Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
The concept stewardship borrows from collective action problems that cannot be solved by individuals only, just like those discussed in environmental ethics.
AMA J Ethics. 2024;26(6):E479-485. doi:
10.1001/amajethics.2024.479.
Dr Keith W. Hamilton joins Ethics Talk to discuss his article, coauthored with Dr George Maliha, Keith Robert Thomas, and Mary Ellen Nepps: “How Might Antibiotic Stewardship Programs Influence Clinicians’ Autonomy and Organizations’ Liability?”